Wegovy's daily weight-loss pill clears TGA, a first for Australia

> Wegovy's daily weight-loss pill just got the green light in Australia, making it the first GLP-1 in oral form to clear the country's medicines regulator. The Therapeutic Goods Administration signed off on the tablet on Tuesday, opening a needle-free option for patients who until now could only take these drugs as weekly injections. Novo Nordisk, the Danish pharma giant behind Wegovy, has already flagged Australia as a priority market.

The TGA confirmed four strengths of the tablet: 1.5mg, 4mg, 9mg and 25mg, according to a spokesperson. Each pill packs semaglutide — and it takes more of it to do the same job. A single 25mg tablet matches the effect of a 2.4mg injection, because the body absorbs the active ingredient less efficiently when it goes through the stomach rather than straight into the bloodstream.

There's a catch before it lands on pharmacy shelves. The TGA still has to review the pill's packaging and production processes to confirm they meet standards, so approval to sell isn't quite the same as availability. Once cleared, patients will still need a doctor's prescription. The approval covers people with obesity as well as those who need to reduce cardiovascular risk.

Paying for it is a separate headache. Under current rules, the Pharmaceutical Benefits Scheme subsidises weight-loss drugs only for people with type 2 diabetes. Australia hasn't set a price guide for the tablet, though in the US the pill generally costs less than the injection despite carrying more semaglutide per dose.

The decision trails similar approvals in the United States and Europe, where demand surged the moment the pill hit the market. In the US, it racked up three million prescriptions in its first five months of availability this year. Novo Nordisk has been contacted for comment on the Australian green light.

The competition isn't sitting still. Rival Eli Lilly, which makes Mounjaro, has its own oral weight-loss drug, Orforglipron, waiting on a TGA decision. Australia's appetite for GLP-1 treatments shows no sign of cooling — and now the pill form is officially in the queue.